Skip to main content

Advertisement

SpringerLink
Log in

FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Regional axillary lymph node status has remained the single most independent variable to predict prognosis both in terms of disease recurrence and survival. This study aimed to prospectively assess sequential [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) findings as early predictors of axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.

Methods

Images were acquired with a PET/CT scanner in 52 patients after administration of FDG (5 MBq/kg) at baseline and after the first, second, third and sixth course of chemotherapy before surgery. Clinical examination and ultrasound (US) were used to assess the size of axillary nodes. Decrease in the standardized uptake value (SUV) with PET corrected or not for partial volume effects was compared to the pathological response.

Results

The sensitivity, specificity and accuracy of axillary node staging was higher with PET (75, 87 and 80%) than with US (50, 83 and 65%), and even more so when PET images were corrected for partial volume effects (86, 83 and 84%). While FDG uptake did not vary much in non-responders, as confirmed by histopathological analysis, it markedly decreased to baseline levels in responders (p < 10−5). Fifty per cent of baseline SUV was considered the best cutoff value to distinguish responders from non-responders. The sensitivity, specificity, negative predictive value and accuracy of FDG PET after one course of chemotherapy were, respectively, 96, 75, 95 and 84%.

Conclusion

The pathological status of regional axillary lymph nodes in stage II and III breast cancer patients could be accurately predicted after one course of neoadjuvant chemotherapy based on FDG PET images.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 1998;25:31–5.

    PubMed  CAS  Google Scholar 

  2. Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83:1480–7.

    Article  PubMed  CAS  Google Scholar 

  3. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304–10.

    Article  PubMed  Google Scholar 

  4. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 2009;115:1194–202.

    Article  PubMed  CAS  Google Scholar 

  5. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11.

    PubMed  CAS  Google Scholar 

  6. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366–72.

    Article  PubMed  Google Scholar 

  7. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931–8.

    PubMed  CAS  Google Scholar 

  8. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806–14.

    PubMed  Google Scholar 

  9. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–88.

    PubMed  CAS  Google Scholar 

  10. Straver ME, Aukema TS, Valdes Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1069–76.

    Article  PubMed  Google Scholar 

  11. Sobin LH, Wittekind Ch. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.

    Google Scholar 

  12. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principles and validation. J Nucl Med 1998;39:904–11.

    PubMed  CAS  Google Scholar 

  13. Ferrer L, Grealou Y, Autret D, et al. A new ImageJ plugin to correct for partial effect volume. Eur J Nucl Med Mol Imaging 2004;31:Suppl 2 (abstract 120).

  14. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging 2006;33:1062–72.

    Article  PubMed  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.

    Article  PubMed  CAS  Google Scholar 

  16. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297–306.

    PubMed  CAS  Google Scholar 

  17. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel of the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940–9.

    Article  PubMed  Google Scholar 

  18. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998;4:230–6.

    PubMed  CAS  Google Scholar 

  19. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80:4–11.

    Article  PubMed  Google Scholar 

  20. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 2006;106:1000–6.

    Article  PubMed  Google Scholar 

  21. Uematsu T, Kasami M, Watanabe J, Takahashi K, Yamasaki S, Tanaka K, et al. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? Breast Cancer 2010 Jun 24 [Epub ahead of print].

  22. Li D, Yao Q, Li L, Chen J. Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007;6:1442–8.

    Article  PubMed  CAS  Google Scholar 

  23. Bruce DM, Evans NT, Heys SD, Needham G, BenYounes H, Mikecz P, et al. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995;21:280–3.

    Article  PubMed  CAS  Google Scholar 

  24. Jansson T, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470–7.

    PubMed  CAS  Google Scholar 

  25. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95.

    PubMed  CAS  Google Scholar 

  26. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500–9.

    PubMed  Google Scholar 

  27. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352–7.

    Article  PubMed  Google Scholar 

  28. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144–50.

    PubMed  Google Scholar 

  29. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, et al. Monitoring primary cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75–84.

    Article  PubMed  CAS  Google Scholar 

  30. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915–24.

    Article  PubMed  CAS  Google Scholar 

  31. Tozaki M, Sakamoto M, Oyama Y, O’uchi T, Kawano N, Suzuki T, et al. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008;28:420–7.

    Article  PubMed  Google Scholar 

  32. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551–7.

    Article  PubMed  CAS  Google Scholar 

  33. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19:1347–57.

    Article  PubMed  Google Scholar 

  34. Thomas A, Ohlinger R, Hauschild M, Mustea A, Blohmer JU, Kümmel S. Options and limits of surgery after pre-operative chemotherapy in breast cancer. Anticancer Res 2006;26:1677–82.

    PubMed  CAS  Google Scholar 

  35. Dalus K, Rendl G, Rettenbacher L, Pirich C. FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1992–3.

    Article  PubMed  Google Scholar 

  36. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041–6.

    Article  PubMed  CAS  Google Scholar 

  37. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–9.

    PubMed  CAS  Google Scholar 

  38. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 2004;31:S103–11.

    Article  PubMed  Google Scholar 

  39. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 1997;3:1565–9.

    PubMed  CAS  Google Scholar 

  40. Ollivier L, Balu-Maestro C, Leclère J. Imaging in evaluation of response to neoadjuvant breast cancer treatment. Cancer Imaging 2005;5:27–31.

    Article  PubMed  CAS  Google Scholar 

  41. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67–76.

    Article  PubMed  Google Scholar 

  42. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007;96:474–80.

    Article  PubMed  Google Scholar 

  43. Javid S, Segara D, Lotfi P, Raza S, Golshan M. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy. Ann Surg Oncol 2010;17:1841–6.

    Article  PubMed  Google Scholar 

  44. Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 2007;63:401–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors’ gratitude goes to the patients of the study, the nuclear medicine technologists at the René Gauducheau, N. Fleury, E. Cerato and M. Vinson. This study was supported by «Conseil Régional des Pays de Loire.»

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Comprehensive Cancer Center René Gauducheau, IRCNA, Saint Herblain, France

    Caroline Rousseau, Boumédiène Bridji & Françoise Kraeber-Bodéré

  2. Cancer Research Center CRCNA, Nantes University, INSERM UMR 892, Nantes, France

    Caroline Rousseau & Françoise Kraeber-Bodéré

  3. Nuclear Medicine Department, Eugène Marquis Cancer Center, Rennes, France

    Anne Devillers

  4. Medical Oncology Department, Comprehensive Cancer Center René Gauducheau, Saint Herblain, France

    Mario Campone

  5. Statistic Department, Comprehensive Cancer Center René Gauducheau, Saint Herblain, France

    Loïc Campion

  6. Medical Physics Department, Comprehensive Cancer Center René Gauducheau, Saint Herblain, France

    Ludovic Ferrer

  7. Pathology Department, University Hospital, Nantes, France

    Christine Sagan

  8. Radiology Department, Comprehensive Cancer Center René Gauducheau, Saint Herblain, France

    Myriam Ricaud

  9. Service de Médecine Nucléaire, Centre René Gauducheau, Boulevard Monod, 44805, Saint Herblain Cedex, France

    Caroline Rousseau

Authors
  1. Caroline Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Devillers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Campone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Loïc Campion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ludovic Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christine Sagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Myriam Ricaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Boumédiène Bridji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Françoise Kraeber-Bodéré
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Rousseau.

Additional information

The study has been presented at the 2006 Annual Meeting of the American Society of Clinical Oncology, Proceedings, 2–6 June, Atlanta, USA. The study has been presented at the 2006 53rd Annual Meeting of the Society of Nuclear Medicine, Oral Presentation, 3–7 June, San Diego, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rousseau, C., Devillers, A., Campone, M. et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 38, 1029–1036 (2011). https://doi.org/10.1007/s00259-011-1735-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1735-y

Keywords

Search

Navigation